Cite
VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo).
MLA
Liu, S. V., et al. “VP5-2021: IMpower133: Gene Expression (GE) Analysis in Long-Term Survivors (LTS) with ES-SCLC Treated with First-Line Carboplatin and Etoposide (CE) ± Atezolizumab (Atezo).” Annals of Oncology, vol. 32, no. 8, Aug. 2021, pp. 1063–65. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.05.799.
APA
Liu, S. V., Mok, T. S. K., Mansfield, A. S., De Boer, R. H., Losonczy, G., Sugawara, S., Krzakowski, M. J., Smolin, A., Hochmair, M. J., Garassino, M. C., Gay, C. M., Heymach, J. V., Byers, L. A., McCleland, M., Nabet, B. Y., Morris, S., Adler, L., Shames, D., & Reck, M. (2021). VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo). Annals of Oncology, 32(8), 1063–1065. https://doi.org/10.1016/j.annonc.2021.05.799
Chicago
Liu, S.V., T.S.K. Mok, A.S. Mansfield, R.H. De Boer, G. Losonczy, S. Sugawara, M.J. Krzakowski, et al. 2021. “VP5-2021: IMpower133: Gene Expression (GE) Analysis in Long-Term Survivors (LTS) with ES-SCLC Treated with First-Line Carboplatin and Etoposide (CE) ± Atezolizumab (Atezo).” Annals of Oncology 32 (8): 1063–65. doi:10.1016/j.annonc.2021.05.799.